RAB1A and breast cancer: Some scholars proposed that good survival outcomes were found in post‐chemotherapy BC patients, and Wang et al. demonstrated that the 5‐year LRFS, DMFS, DFS and OS rates of post‐chemotherapy BC patients were 88%, 79%, 73%, and 81%, respectively, but rare studies focused on the prognosis of patients with post‐chemotherapy ypT1‐2ypN1.19, 20, 21